Qiagen (QGEN - Snapshot Report) and Genome Diagnostics recently expanded their partnership agreement for the development and commercialization of new molecular tests for the detection of genetic variations in human leukocyte antigen (HLA).Genome will develop these molecular tests based on Qiagen’s proprietary Pyrosequencing and other sequencing technologies. These state-of-the-art technologies will facilitate an accurate analysis of HLA sequences in a prompt and cost-effective manner, and will also help detect unknown polymorphisms directly.
HLA genes are connected with many diseases as well as the response of patients to drugs. HLA testing helps in the evaluation of risks associated with particular diseases and in developing tailored treatments for the same. This sequence-based HLA test is a significant addition to the molecular diagnostic portfolio for the prevention of diseases as well as for enabling of personalized health care.
Qiagen is a leading provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection.
The Qiagen–Genome partnership dates back to August 2006. Genome develops and produces innovative assays and analyses software for high-resolution tissue typing for transplantation medicine and companion diagnostics.
Through the introduction of new tests, Qiagen expects to leverage its leadership position in the research, pharmaceutical, and applied testing markets, and to expand into a rapidly growing molecular diagnostics market.
As of the end of first-quarter 2010, the company’s consumable portfolio represented approximately 86% of total net sales, with the largest revenue share of about 45% coming in from sales to customers in molecular diagnostics. Qiagen intends to capture more test markets, thereby boosting its revenue.
No comments:
Post a Comment